107 related articles for article (PubMed ID: 14619469)
1. [Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Kawaguchi Y; Sugiyama Y; Saji S
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1583-6. PubMed ID: 14619469
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer].
Sugiyama Y; Saji S; Miya K; Kunieda K; Takao H; Kawaguchi Y; Kimura A; Honda S; Matsui K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1616-9. PubMed ID: 11707993
[TBL] [Abstract][Full Text] [Related]
3. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
[TBL] [Abstract][Full Text] [Related]
4. [Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Kikumori T; Hayashi H; Shibata A; Sekiya M; Itoh T; Mase T; Oiwa M; Imai T; Funahashi H
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2091-4. PubMed ID: 10584578
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
6. [Local immunotherapy of breast cancer: a case of advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2].
Fujimori M; Sugenoya A; Kobayashi S; Masuda H; Komatsu M; Takahashi S; Shimizu T; Tsuchiya S; Iida F
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2760-3. PubMed ID: 2551219
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
8. [Intra-arterial infusion chemotherapy for unresectable or recurrent breast cancer].
An M; Matsumoto Y; Kishi T; Terakado H; Ikawa M; Hamada E; Watanabe Y; Nakasato S; Murata M; Takaki S; Miura T; Idezuki Y; Kobayashi M
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1330-2. PubMed ID: 9703820
[TBL] [Abstract][Full Text] [Related]
9. [Local treatment of locally recurrent breast cancers].
Asaishi K; Okazaki M; Hayasaka H
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1325-30. PubMed ID: 3382202
[TBL] [Abstract][Full Text] [Related]
10. [Locoregional injection of OK-432/fibrinogen/thrombin for unresectable metastatic liver tumors].
Yoshida T; Osato H; Sakon M; Monden T; Amano M; Aoki T; Kishimoto S; Umeshita K; Dono K; Gotoh M; Monden M
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1575-7. PubMed ID: 8854809
[TBL] [Abstract][Full Text] [Related]
11. Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Amano M; Sekimoto M; Monden T; Tomita N; Ohue M; Haba A; Sakita I; Tamaki Y; Monden M
Dis Colon Rectum; 2000 Mar; 43(3):402-7. PubMed ID: 10733124
[TBL] [Abstract][Full Text] [Related]
12. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
14. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
15. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
[TBL] [Abstract][Full Text] [Related]
16. [Clinical studies on chemo-immunotherapy for advanced and recurrent carcinoma of the breast].
Kikuchi K; Takahashi N
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1476-81. PubMed ID: 3925888
[TBL] [Abstract][Full Text] [Related]
17. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
Jang JW; Park YM; Bae SH; Choi JY; Yoon SK; Chang UI; Nam SW; Kim BS
Cancer Chemother Pharmacol; 2004 Nov; 54(5):415-20. PubMed ID: 15235823
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
20. Role of urokinase-type plasminogen activator in local immunotherapy.
Takeda T; Ito Y; Wakasugi E; Kobayashi T; Monden M
Oncol Rep; 1998; 5(2):329-33. PubMed ID: 9468551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
